Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine vs Bupivacaine in Mohs Surgery
NCT03871478Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of bupivacaine in non-melanoma skin cancer (NMSC) (3 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Wong-Baker FACES Pain Rating Scale at 72 hours. Status: unknown.
02
Drugs
bupivacaine
03
Conditions
non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT03871478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871478.